阿立哌唑与利培酮治疗精神分裂症对照研究

目的 比较阿立哌唑与利培酮治疗精神分裂症的疗效及安全性.方法 将60例精神分裂症患者随机分为两组,每组30例,研究组口服阿立哌唑治疗,对照组口服利培酮治疗,观察8周.于治疗前及治疗2周、4周、6周、8周末采用阳性与阴性症状量表及副反应量表评定临床疗效和不良反应.并于治疗前后测定血清催乳素水平.结果 治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前有显著下降(P＜0.05或0.01),同期两组间评分差异均无显著性(P＞0.05);治疗8周末,研究组显效率76.7%,有效率90.0%,对照组分别为73.3%和93.3%,两组差异无显著性(P＞0.05).研究组治疗前催乳素水平与对照组无显著性差异,治疗后显著低于对照组(P＜0.01);两组不良反应均轻微,但研究组静坐不能、体重增加及月经紊乱/泌乳发生率均显著低于对照组(P＜0.05),而口干发生率显著高于对照组(P＜0.05).结论 阿立哌唑与利培酮治疗精神分裂症疗效均显著,但阿立哌唑安全性更高,依从性更好,不影响催乳素水平,可作为一线抗精神病药物在临床推广应用.

A controlled study of aripiprazole vs.risperidone in the treatment of schizophrenia

Objective To compare the efficacy and safety of aripiprazole vs. risperidone in the treatment of schizophrenia. Methods Sixty patients with schizophrenia were randomly divided into two groups of 30 ones each, ersearch group took orally aripiprazole and control group did risperidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and side effects with the Treatment Emergent Symptom Scale （TESS） at intake and at the end of the 2th , 4th , Bth and 8th week treatment. Serum prolactin levels were detected at intake. Results After treatment, the total and each factor scores of the PANSS lowered more significantly compared with pretreatment （P〈0.05 or 0.01）, there were no significant differences in contemporary group comparisons （P〉0.05） ; at the end of the 8th week, obvious effective and effective rates were 76.7% and 90.0% in the research and 73.3% and 93.3% in the control,which showed no signifeant differences （P〉0.05）. Serum prolactin levels in the research had no significant differences from the control before treatment, but were significantly lower after treatment （P〈 0.01） ; adverse reactions of both groups were mild, incidences of akathisia, weight gain, menstrual disorder and lactation were significantly lower in the research than in the control group （P〈0.05）, but those of dry mouth higher （P〈0.05）. Conclusion Both aripiprazole and risperidone are effective on schizophrenia, but aripiprazole has higher safety and better compliance, can＇t influence prolactin levels, and could be used as first-line antipsychotic drug.